Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcitriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GC | P02774 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcitriol SCHEMBL3488822 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL2641696 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL2733051 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL15169024 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL24066838 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL14027727 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL23386523 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL13989116 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL17973736 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL21055106 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246032-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLEDRONIC ACID, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISEASES RELATED TO BONE METABOLISM AND OF TREATMENT-RELATED SIDE EFFECTS SUCH AS HYPOCALCAEMIA | KARL CHRISTOPH (CH) | 2021-08-11 | — | — | EP | claimed |
| EP-3458093-A1 | PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISORDERS OF THE BONE METABOLISM AND THERAPY-INDUCED SIDE EFFECTS SUCH AS HYPOCALCEMIA | Karl, Christoph (CH) | 2019-03-27 | — | — | EP | claimed |
| WO-2017198811-A1 | PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISORDERS OF THE BONE METABOLISM AND THERAPY-INDUCED SIDE EFFECTS SUCH AS HYPOCALCEMIA | KARL CHRISTOPH (CH) | 2017-11-23 | — | — | WO | claimed |
| EP-3246032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLEDRONIC ACID, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISEASES RELATED TO BONE METABOLISM AND OF TREATMENT-RELATED SIDE EFFECTS SUCH AS HYPOCALCAEMIA | Karl, Christoph (CH) | 2017-11-22 | — | — | EP | claimed |
| CN-103391920-A | Calcium-sensing receptor-active compounds | LEO PHARMA AS | 2013-11-13 | — | — | CN | claimed |
| CN-103270018-A | Calcium-sensing receptor-active compounds | LEO PHARMA AS | 2013-08-28 | — | — | CN | claimed |
| CN-103228619-A | Calcium-sensing receptor-active compounds | LEO PHARMA AS | 2013-07-31 | — | — | CN | claimed |
| CN-102958907-A | New polymorphic form of calcimimetic compound | LEO PHARMA AS | 2013-03-06 | — | — | CN | claimed |
| CN-102958908-A | Novel polymorphic forms of a calcimimetic compound | LEO PHARMA AS | 2013-03-06 | — | — | CN | claimed |
| CN-101516360-A | Substituted acetylenic compounds useful for the treatment of diseases | LEO PHARMA AS (DK) | 2009-08-26 | — | — | CN | claimed |
| US-20240009119-A1 | RAPIDLY INFUSING COMPOSITIONS WITH SUPPLEMENTS AND TREATMENT METHODS | Orcosa Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| CN-117281825-A | Compound vitamin pharmaceutical preparation for broiler chickens and preparation method and application thereof | 商丘师范学院 | 2023-12-26 | — | — | CN | disclosed |
| CN-113777191-A | Method for determining content of calcitriol soft capsule | 芜湖职业技术学院 | 2021-12-10 | — | — | CN | disclosed |
| WO-2021033003-A1 | HORMONE D (VITAMIN D) AND ITS DERIVATIVES FOR THE TREATMENT AND PREVENTION OF CANCER | INDUSTRIAL TECHNOLOGIES & BIOTECHNOLOGIES (CH) | 2021-02-25 | — | — | WO | disclosed |
| EP-3320952-B1 | TREATMENT OF MULTIPLE SCLEROSIS | WISCONSIN ALUMNI RES FOUND (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-1169425-A | Fluorinated vitamin D3 analogs | HOFFMANN LA ROCHE (CH) | 1998-01-07 | — | — | CN | disclosed |
| EP-0726892-A1 | (E)-20(22)-DEHYDROVITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-08-21 | — | — | EP | disclosed |
| CN-1112918-A | Fluorinated vitamin D3 derivative | HOFFMANN LA ROCHE (CH) | 1995-12-06 | — | — | CN | disclosed |
| CN-1108245-A | Vitamin D3 analogs | HOFFMANN LA ROCHE (CH) | 1995-09-13 | — | — | CN | disclosed |
| WO-1995012575-A1 | (E)-20(22)-DEHYDROVITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-05-11 | — | — | WO | disclosed |